327 related articles for article (PubMed ID: 31841726)
1. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
Hakim A; Braun H; Thornton D; Strymish J
Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
[TBL] [Abstract][Full Text] [Related]
2. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
3. Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus.
Chesi G; Colli A; Mestres CA; Gambarati G; Boni F; Gherli T
BMC Infect Dis; 2006 Jul; 6():124. PubMed ID: 16872491
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
5. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
[TBL] [Abstract][Full Text] [Related]
6. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
7. Treatment of tricuspid valve endocarditis with daptomycin and linezolid therapy.
Galanter KM; Ho J
Am J Health Syst Pharm; 2019 Jul; 76(14):1033-1036. PubMed ID: 31201773
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Esposito S; Noviello S; Leone S
Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
[TBL] [Abstract][Full Text] [Related]
9. Tricuspid and mitral endocarditis due to methicillin-resistant Staphylococcus aureus exhibiting vancomycin-creep phenomenon.
Sundaragiri PR; Vallabhajosyula S; Haddad TM; Esterbrooks DJ
BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26531738
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid.
Souli M; Pontikis K; Chryssouli Z; Galani I; Giamarellou H
Eur J Clin Microbiol Infect Dis; 2005 Nov; 24(11):760-2. PubMed ID: 16283218
[No Abstract] [Full Text] [Related]
11. Use of daptomycin in a pregnant patient with Staphylococcus aureus endocarditis.
Stroup JS; Wagner J; Badzinski T
Ann Pharmacother; 2010 Apr; 44(4):746-9. PubMed ID: 20197474
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
[TBL] [Abstract][Full Text] [Related]
13. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of right-sided native valve methicillin-resistant Staphylococcus aureus endocarditis and septicaemia with teicoplanin and rifampicin: a case report.
Saravu K; Mukhopadhyay C; Satyanarayanan V; Pai A; Komaranchath AS; Munim F; Shastry BA; Tom D
Scand J Infect Dis; 2012 Jul; 44(7):544-7. PubMed ID: 22385220
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.
Tobudic S; Forstner C; Burgmann H; Lagler H; Ramharter M; Steininger C; Vossen MG; Winkler S; Thalhammer F
Clin Infect Dis; 2018 Aug; 67(5):795-798. PubMed ID: 29659732
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcal endocarditis in a quadricuspid aortic valve following uncomplicated dengue infection: a case report.
Weerasooriya N; Fernando T; Serasinghe P; Alahakoon B; Madurapperuma C; Jayanaga A
BMC Infect Dis; 2020 Aug; 20(1):583. PubMed ID: 32762676
[TBL] [Abstract][Full Text] [Related]
18. [Dalbavancin and its use in the treatment of methicillin-resistant Staphylococcus aureus - induced upper limb phlegmon].
Zahornacký O; Novotný M
Klin Mikrobiol Infekc Lek; 2020 Jun; 26(2):51-53. PubMed ID: 33389741
[TBL] [Abstract][Full Text] [Related]
19. Failure of medical therapy in tricuspid endocarditis due to Staphylococcus aureus.
Geiseler PJ; Rice TW; McCulley DJ; Lewis SM; Berzins BL
Chemotherapy; 1984; 30(6):408-12. PubMed ID: 6518837
[TBL] [Abstract][Full Text] [Related]
20. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
